[go: up one dir, main page]

NO934897D0 - Fremgangsmaate for fremstilling av et farmasoeytisk preparat - Google Patents

Fremgangsmaate for fremstilling av et farmasoeytisk preparat

Info

Publication number
NO934897D0
NO934897D0 NO934897A NO934897A NO934897D0 NO 934897 D0 NO934897 D0 NO 934897D0 NO 934897 A NO934897 A NO 934897A NO 934897 A NO934897 A NO 934897A NO 934897 D0 NO934897 D0 NO 934897D0
Authority
NO
Norway
Prior art keywords
preparing
procedure
pharmaceutical preparation
pharmaceutical
preparation
Prior art date
Application number
NO934897A
Other languages
English (en)
Other versions
NO302176B1 (no
NO934897L (no
Inventor
Mary Kathleen Shriver
Elaine K Thomas
Wesley L Cosand
Larry H Gosting
Edna S Dickinson
Janela Mcclure
George J Todaro
Robert C Nowinski
Original Assignee
Genetic Systems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Systems Corp filed Critical Genetic Systems Corp
Publication of NO934897L publication Critical patent/NO934897L/no
Publication of NO934897D0 publication Critical patent/NO934897D0/no
Publication of NO302176B1 publication Critical patent/NO302176B1/no

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04B—POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS
    • F04B25/00—Multi-stage pumps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K16/1143—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO934897A 1986-08-20 1993-12-29 Fremgangsmåte for fremstilling av et monoklonalt antistoff og et antigen NO302176B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89827386A 1986-08-20 1986-08-20
US4502687A 1987-05-01 1987-05-01
US6799687A 1987-06-29 1987-06-29

Publications (3)

Publication Number Publication Date
NO934897L NO934897L (no) 1993-12-29
NO934897D0 true NO934897D0 (no) 1993-12-29
NO302176B1 NO302176B1 (no) 1998-02-02

Family

ID=27366600

Family Applications (2)

Application Number Title Priority Date Filing Date
NO873495A NO300462B1 (no) 1986-08-20 1987-08-19 Monoklonale antistoffer og peptider som kan anvendes til diagnose av HIV-infeksjoner
NO934897A NO302176B1 (no) 1986-08-20 1993-12-29 Fremgangsmåte for fremstilling av et monoklonalt antistoff og et antigen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO873495A NO300462B1 (no) 1986-08-20 1987-08-19 Monoklonale antistoffer og peptider som kan anvendes til diagnose av HIV-infeksjoner

Country Status (28)

Country Link
JP (1) JPS6485928A (no)
KR (1) KR920008744B1 (no)
AT (1) AT398080B (no)
AU (1) AU616156B2 (no)
BE (1) BE1000811A4 (no)
CH (1) CH675728A5 (no)
CS (1) CS275838B6 (no)
DE (1) DE3727703A1 (no)
DK (1) DK433087A (no)
ES (1) ES2010727A6 (no)
FI (1) FI873553A7 (no)
FR (1) FR2603107B1 (no)
GB (1) GB2196634B (no)
GR (1) GR871298B (no)
HU (1) HU214439B (no)
IE (1) IE60671B1 (no)
IL (1) IL83580A (no)
IT (1) IT1222518B (no)
LU (1) LU86972A1 (no)
NL (1) NL8701950A (no)
NO (2) NO300462B1 (no)
NZ (1) NZ221440A (no)
OA (1) OA08652A (no)
PL (1) PL155084B1 (no)
PT (1) PT85567B (no)
SE (1) SE506025C2 (no)
YU (1) YU152587A (no)
ZW (1) ZW15487A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP96A (en) * 1986-06-03 1990-08-12 The Usa Dept Of Commerce Small peptides which inhibit binding to T-4 receptors and act as immunogens.
AU625720B2 (en) * 1987-05-01 1992-07-16 Genetic Systems Corporation Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
JP2520464B2 (ja) * 1987-05-29 1996-07-31 タノツクス・バイオシステムズ・インコーポレーテツド Ｈｉｖ―１を中和するモノクロ―ナル抗体
US5981278A (en) * 1987-05-29 1999-11-09 Tanox, Inc. Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
US6657050B1 (en) 1987-05-29 2003-12-02 Tanox, Inc. Chimeric viral-neutralizing immunoglobulins
WO1989007112A1 (en) * 1988-01-26 1989-08-10 The United States Of America, As Represented By Th A synthetic antigen evoking anti-hiv response
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
IL90048A0 (en) * 1988-04-25 1989-12-15 Merck & Co Inc Recombinant gag precursor of hiv,its preparation and its use as aids vaccine
US5562905A (en) * 1988-04-26 1996-10-08 E. I. Du Pont De Nemours And Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
FR2632310B1 (fr) * 1988-06-06 1992-04-10 Pasteur Institut Peptides ayant des proprietes protectrices d'un virus pathogene du type hiv dans des cellules sensibles
AU640619B2 (en) * 1988-10-03 1993-09-02 Repligen Corporation Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
CA2025481A1 (en) * 1989-09-19 1991-03-20 Peter J. Kniskern Vaccine for aids and hepatitis b
SE9000333D0 (sv) * 1990-01-31 1990-01-31 Britta Wahren Monoklonal antikropp
SE468168B (sv) * 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
JPH03271233A (ja) * 1990-03-19 1991-12-03 Inst Pasteur ウイルスエンベロープ糖タンパク質及びその糖タンパク質の中和エピトープに対応するペプチドの間の相乗作用による、ウイルス性感染に対する防御の誘発
CA2047042A1 (en) * 1990-07-19 1992-01-20 John Hannah Cyclic hiv principal neutralizing determinant peptides
CA2047078A1 (en) * 1990-07-19 1992-01-20 Steven S. Bondy Cyclic hiv principal neutralizing determinant peptides
JPH05310785A (ja) * 1991-09-30 1993-11-22 Nitto Denko Corp Ｈｉｖ関連環状ペプチドおよびこれを固定化した吸着体
PT960886E (pt) * 1992-03-27 2004-10-29 Advanced Immunit T Inc Peptido t e peptidos relacionados no tratamento de inflamacao; incluindo esclerose multipla
ES2523858T3 (es) 2005-12-09 2014-12-02 Vectus Biosystems Limited Fragmentos de VIP y composiciones de los mismos
EP2323233B1 (en) 2008-09-02 2017-10-11 NGK Spark Plug Co., Ltd. Spark plug
KR102727239B1 (ko) * 2022-09-07 2024-11-07 한국세라믹기술원 산화 마그네슘　분말 및 그의 제조방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
IE64006B1 (en) * 1984-10-18 1995-06-28 Pasteur Institut Antigens particulary envelope antigens of the virus of lymphadenopathies and of the acquired immune-deficiency syndrome and virus process for producing virus envelope antigens use of said antigens in the preparation of immunogenic compositions or for the diagnosis of the presence of antibodies against this virus
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
IE64785B1 (en) * 1985-04-08 1995-09-06 Genetic Systems Corp Expression of immunologically reactive viral proteins
EP0220234B1 (en) * 1985-04-08 1994-08-03 Genetic Systems Corporation EXPRESSION AND DIAGNOSTIC USE OF gag ENCODED PEPTIDES WHICH ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO LAV
DK171119B1 (da) * 1985-04-19 1996-06-17 Hoffmann La Roche AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin
ATE116006T1 (de) * 1985-04-29 1995-01-15 Genetic Systems Corp Synthetische antigene zum nachweis von aids.
GB8525615D0 (en) * 1985-10-17 1985-11-20 Hoffmann La Roche Polypeptides
DE3689941D1 (de) * 1985-10-24 1994-08-04 Southwest Found Biomed Res Synthetische peptide und deren verwendung zur diagnose und impfung für aids und arc.
JP2837669B2 (ja) * 1985-11-07 1998-12-16 プレジデント アンド フエロウズ オブ ハ−バ−ド カレツジ Ｔ−細胞リンパ趨行性ウイルス蛋白及びその分析
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
DK169582B1 (da) * 1986-06-23 1994-12-12 Squibb Bristol Myers Co Humant monoklonalt antistof, der er i stand til at reagere med en epitop på LAV/HTLV-III kappeglycoproteinet gp41, cellelinier, som producerer sådant antistof, farmaceutisk præparat indeholdende antistoffet samt fremgangsmåde til bestemmelse af nærværelsen af LAV/HTLV-III i en biologisk prøve og fremgangsmåde til separering af specifikke antigendeterminanter af LAV/HTLV-III under anvendelse af ant
EP0255190A3 (en) * 1986-08-01 1990-08-29 Repligen Corporation Recombinant polypeptides and their uses, inclusing assay for aids virus
AU592258B2 (en) * 1986-12-30 1990-01-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins

Also Published As

Publication number Publication date
ES2010727A6 (es) 1989-12-01
IL83580A (en) 1992-11-15
PL267401A1 (en) 1988-07-21
FI873553A0 (fi) 1987-08-17
SE8703225D0 (sv) 1987-08-19
DE3727703A1 (de) 1988-05-05
HU214439B (hu) 1998-03-30
LU86972A1 (fr) 1988-03-02
CS275838B6 (en) 1992-03-18
KR920008744B1 (ko) 1992-10-09
KR890002547A (ko) 1989-04-10
DK433087A (da) 1988-02-21
FI873553L (fi) 1988-02-21
CH675728A5 (no) 1990-10-31
SE8703225L (sv) 1988-02-21
PL155084B1 (en) 1991-10-31
FR2603107A1 (fr) 1988-02-26
CS8706136A2 (en) 1990-08-14
GB8719587D0 (en) 1987-09-23
ATA208987A (de) 1994-01-15
AU616156B2 (en) 1991-10-24
IL83580A0 (en) 1988-01-31
NO873495D0 (no) 1987-08-19
BE1000811A4 (fr) 1989-04-11
IT8721678A0 (it) 1987-08-19
GR871298B (en) 1988-01-12
AU7720187A (en) 1988-05-19
NL8701950A (nl) 1988-03-16
YU152587A (sh) 1992-09-07
NO302176B1 (no) 1998-02-02
JPS6485928A (en) 1989-03-30
NO934897L (no) 1993-12-29
PT85567A (en) 1987-09-01
FI873553A7 (fi) 1988-02-21
NO300462B1 (no) 1997-06-02
GB2196634A (en) 1988-05-05
FR2603107B1 (fr) 1992-04-24
HUT44619A (en) 1988-03-28
ZW15487A1 (en) 1988-09-14
IE872219L (en) 1988-02-20
IE60671B1 (en) 1994-08-10
NO873495L (no) 1988-02-22
NZ221440A (en) 1991-11-26
GB2196634B (en) 1991-05-15
OA08652A (fr) 1988-11-30
DK433087D0 (da) 1987-08-19
SE506025C2 (sv) 1997-11-03
PT85567B (pt) 1991-02-08
IT1222518B (it) 1990-09-05
AT398080B (de) 1994-09-26

Similar Documents

Publication Publication Date Title
NO882103D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
NO173213C (no) Fremgangsmaate for fremstilling av et preparat omfattende et liposom
NO934897D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
NO885641D0 (no) Fremgangsmaate for fremstilling av farmasoeytisk preparat.
NO880520L (no) Fremgangsmaate for fremstilling av et cholestyraminpreparat
NO175286C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat som omfatter dobbeltveggede mikrokapsler
NO903264L (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat i form av mikropartikler.
FI884636L (fi) Pitkävaikutteisen farmaseuttisen valmisteen valmistusmenetelmä
NO173486C (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat for transdermal administrasjon av legemidler
FI894637A0 (fi) Menetelmä mikroemulsion käsittävän farmaseuttisen formulaation valmistamiseksi
NO170516C (no) Fremgangsmaate for fremstilling av en formulering av beclomethasondipropionat
NO892826L (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat for aa forhindre seksuelt overfoerbare sykdommer.
FI892640A0 (fi) Menetelmä piperidinoalkanoli-ibuprofeeniyhdistelmää sisältävän farmaseuttisen koostumuksen valmistamiseksi
FI873106L (fi) Menetelmä jatkuvavapautteisen lääkevalmisteen valmistamiseksi
NO172447C (no) Fremgangsmaate for fremstilling av b-avermectiner
NO883054D0 (no) Fremgangsmaate for fremstilling av farmasoeytisk preparat inneholdende somatostatinanaloger.
NO901232L (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
NO884052D0 (no) Fremgangsmaate for fremstilling av et terapeutisk preparat.
NO173590C (no) Fremgangsmaate for fremstilling av et stabilt nikorandilholdig farmasoeytisk preparat
NO870368D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat med langvarig virkning.
NO870866L (no) FremgangsmŸte for fremstilling av et terapeutisk kombinasjonspreparat.
FI884240L (fi) Menetelmä paikalliseen käyttöön tarkoitetun farmaseuttisen valmisteen valmistamiseksi
NO177485C (no) Fremgangsmåte for fremstilling av et farmasöytisk inhalasjonspreparat
NO171792C (no) Fremgangsmaate for fremstilling av en friradikal-addisjonspolymer
NO171910C (no) Fremgangsmaate for fremstilling av 1-alkyl-5-nitroimidazoler